Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
XOMA RoyaltyXOMA -0.10%41 3-Year ROIIC % is 28.78 as of Dec. 2025, which is 276% above its 10-year median of 7.66. GuruFocus rates XOMA with a GF Score™ of 41/100 and a GF Value™ of $18.95 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 1,322 Biotechnology companies, XOMA Royalty ranks better than 67.93% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
XOMA Royalty's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 28.78%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for XOMA Royalty's 3-Year ROIIC % or its related term are showing as below:
XOMA's 3-Year ROIIC % is ranked better than 67.93% of 1322
companies
in the Biotechnology industry
Industry Median: -4.9
vs XOMA: 28.78
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
XOMA Royalty 3-Year ROIIC % Related Terms
XOMA Royalty 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for XOMA Royalty's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XOMA vs CLYM, CTMX, ALLO: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, XOMA Royalty's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
XOMA Royalty 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, XOMA Royalty's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where XOMA Royalty's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
XOMA Royalty (XOMA) has a 3-Year ROIIC % of 28.78 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on XOMA Royalty and its competitors. This is 276% above median its historical median of 7.66. According to the industry distribution chart, XOMA Royalty ranks #424 out of 1322 companies in the Biotechnology industry, placing it in the top 32.1%.
Is XOMA Royalty's 3-Year ROIIC % too high?
XOMA Royalty's current 3-Year ROIIC % of 28.78 is 276% above median its 10-year median of 7.66. Based on the distribution chart, XOMA Royalty ranks #424 out of 1322 companies in the Biotechnology industry, which is above the industry midpoint. Overall, XOMA Royalty has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does XOMA Royalty's 3-Year ROIIC % compare to CLYM and CTMX?
According to the Biotechnology industry distribution chart, XOMA Royalty ranks #424 out of 1322 companies for 3-Year ROIIC %. This puts XOMA Royalty in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on XOMA Royalty and its competitors. XOMA Royalty's current 3-Year ROIIC % is 28.78, which is 276% above median its own 10-year median of 7.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is XOMA Royalty stock overvalued right now?
Based on GuruFocus' analysis, XOMA Royalty (XOMA) is currently considered Significantly Overvalued. The stock's GF Value™ is $18.95, compared to a current price of $40.17 — trading 112% above its estimated fair value. The current 3-Year ROIIC % is 28.78, which is 276% above median its 10-year median of 7.66. XOMA Royalty's overall GF Score™ is 41/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For XOMA Royalty (XOMA), the current 3-Year ROIIC % is 28.78 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is XOMA Royalty (XOMA) Overvalued in 2026?
Based on GuruFocus' analysis, XOMA Royalty stock appears to be overvalued.
The current stock price of $40.17 is trading 112% above its estimated GF Value™ of $18.95.
GuruFocus considers XOMA Royalty to be Significantly Overvalued.
Key valuation signals for XOMA:
3-Year ROIIC %: 28.78 (276% above median its 10-year median of 7.66)
GF Value™: $18.95 vs. price of $40.17 (112% above fair value)
No single metric tells the full story. See the XOMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates. The Company's drug royalty aggregator business is mainly focused on the acquisition of early to mid-stage clinical assets. Geographically, the company operates in Switzerland, the United States, Asia Pacific, Europe, and other regions.
41GF Score
Get the complete analysis for XOMA
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XOMA has been successfully added to your 
